This Article Figures Only Full Text Full Text (PDF) Correction (v54,p1635) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Al Jaroudi, W. Articles by Iskandrian, A. E. Search for Related Content PubMed PubMed Citation Articles by Al Jaroudi, W. Articles by Iskandrian, A. E. Related Collections Related Article

STATE-OF-THE-ART PAPER

Regadenoson: A New Myocardial Stress Agent

Division of Cardiovascular Diseases, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama

Manuscript received January 22, 2009; revised manuscript received March 10, 2009, accepted April 26, 2009.

^_* Reprint requests and correspondence: Dr. Wael Al Jaroudi, 701 19th Street, LHRB 306, Birmingham, Alabama 35294 (Email: waljaroudi{at}cardmail.dom.uab.edu).

Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike adenosine, is a selective A_2A agonist that is given as an intravenous bolus at a fixed dose, with less undesirable side effects including atrioventricular block and bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate reactive airway disease. This review will summarize the pre-clinical and clinical data on regadenoson, as they specifically relate to its use as a vasodilator stress agent, currently the only approved selective A_{2A agonist.}

Key Words: adenosine • regadenoson • myocardial perfusion imaging • single-photon emission computed tomography • stress testing

Abbreviations and Acronyms   COPD = chronic obstructive pulmonary disease   FDA = Food and Drug Administration   FEV1 = forced expiratory volume (1 s)   LV = left ventricle/ventricular   MBF = myocardial blood flow   MPI = myocardial perfusion imaging

Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A27. [Full Text] [PDF]

This article has been cited by other articles:

				T. R. Porter, M. Adolphson, R. R. High, L. M. Smith, J. Olson, M. Erdkamp, F. Xie, E. O'Leary, B. F. Wong, S. Eifert-Rain, et al. Rapid Detection of Coronary Artery Stenoses With Real-Time Perfusion Echocardiography During Regadenoson Stress Circ Cardiovasc Imaging, November 1, 2011; 4(6): 628 - 635. [Abstract] [Full Text] [PDF]

				P. K. Nair, O. C. Marroquin, S. R. Mulukutla, S. Khandhar, V. Gulati, J. T. Schindler, and J. S. Lee Clinical Utility of Regadenoson for Assessing Fractional Flow Reserve J. Am. Coll. Cardiol. Intv., October 1, 2011; 4(10): 1085 - 1092. [Abstract] [Full Text] [PDF]

				B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, and C. E. Muller International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update Pharmacol. Rev., March 1, 2011; 63(1): 1 - 34. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al. Highlights of the Year in JACC 2009 J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407. [Full Text] [PDF]